THE IMPACT OF ATG/ALC RATIO ON OUTCOME IN ADULT PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANT FOR HEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE SINGLE CENTER ANALYSIS. (EHA 2026) - May 13, 2026 - Abstract #EHA-6388; PB4003; "Background Rabbit anti-thymocyte globulin (ATG) is widely used for graft-versus-host disease (GVHD) prophylaxis in matched related and unrelated donor allogeneic hematopoietic stem cell transplantation (allo-HSCT), with randomized trials showing reduced acute and chronic GVHD. Given the immunomodulatory effect of ATG, CMV reactivation should be, partially, interpreted within the context of pre-letermovir practice. Larger multicentre prospective studies are required to validate ALC-guided dosing and better define the therapeutic window balancing GVHD, relapse, and infectious risk in matched donor allo-HSCT."
Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Transplantation
|
|
Giuseppe Sapienza 1; Corinne Spoto 1; Roberto Bono 1; Cristina Rotolo 1; Luca Castagna1
|